This chart shows why the hullabaloo over the 12-year exclusivity period for US biologics is much ado about nothing (#msg-59912094). For every big-selling biologic, US patent protection continues longer than the statutory exclusivity period.
(The 12-year exclusivity could become consequential if the US patents on these drugs were found to be unenforceable, but there’s no indication that such an outcome is likely.)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.